A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

← catalyst calendar

NCT05643742 · readout ≤ 1,260 d

Sponsored by CRISPR Therapeutics AG (industry) · CRSP — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

120estimated

Sites

Countries

Australia, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-03-10

actual

When the study began enrolling

Primary completion

Jan 2030

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Feb 2030

estimated

The whole study's end, after follow-up

First posted

2022-12-09

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2025-11-14

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

B-cell Lymphoma
Non-Hodgkin Lymphoma
B-cell Malignancy
Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Follicular Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Large B-cell Lymphoma

Intervention

Biological: CTX112

Primary outcomes

what the primary-completion date above is the date OF

Phase 1 (Dose Escalation): Incidence of adverse events, defined as dose-limiting toxicities

measured From CTX112 infusion up to 28 days post-infusion

Phase 2 (Cohort Expansion): Objective response rate

measured From CTX112 infusion up to 60 months post-infusion

Permalink · CRSP's whole pipeline · Catalyst calendar · Every registered study · What changed